Text Size

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer

This study is currently recruiting participants.
Verified December 2011 by King Faisal Specialist Hospital & Research Center
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT01311037
First received: March 6, 2011
Last updated: December 11, 2011
Last verified: December 2011
History of Changes
  Purpose

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.


Condition Intervention
Advanced Breast Cancer
 Other: GnRh Analogue and Aromatase Inhibitor

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer A Prospective Trial

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by King Faisal Specialist Hospital & Research Center:

Estimated Enrollment: 2
Study Start Date: January 2009
Intervention Details:
    Other: GnRh Analogue and Aromatase Inhibitor
    GnRh Analogue and Aromatase Inhibitor
    Other Name: GnRh Analogue and Aromatase Inhibitor
Detailed Description:

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

  Eligibility

Ages Eligible for Study:   45 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Receptor Positive Premenopausal Women with Advanced Breast Cancer.

Criteria

Inclusion Criteria:

  • Receptor Positive Premenopausal Women with Advanced Breast Cancer.

Exclusion Criteria:

  • Any woman other than diagnosis of Receptor Positive Premenopausal with Advanced Breast Cancer.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01311037

Contacts
Contact: Al Sayed, M.D. +966-1-4423949

Locations
Saudi Arabia
Kfsh & Rc Recruiting
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Al Sayed, M.D. KFSH & RC
  More Information

No publications provided

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01311037     History of Changes
Other Study ID Numbers: RAC# 2081-064, RAC# 2081-064
Study First Received: March 6, 2011
Last Updated: December 11, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by King Faisal Specialist Hospital & Research Center:
Premenopausal Women with Advanced Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
 Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013